Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.73 |
| ▸ | PI4KA | P42356 | 3/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.67 |
| ▸ | NSD3 | Q9BZ95 | 5/20 | 0.57 |
| ▸ | NSD2 | O96028 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11222112 | 0.91 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL67131 | 0.90 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL4906617 | 0.88 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL38913 | 0.87 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL2638103 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12925855 | 0.85 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL14037129 | 0.85 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL218588 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL2638100 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL15841807 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501850-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2003093290-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | claimed |
| US-10077284-B2 | UBA5 inhibitors | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2018-09-18 | — | — | US | disclosed |
| US-20170107247-A1 | UBA5 INHIBITORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-04-20 | — | — | US | disclosed |
| US-20170107247-A1 | UBA5 INHIBITORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-04-20 | — | — | US | disclosed |
| US-20170107247-A1 | UBA5 INHIBITORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-04-20 | — | — | US | disclosed |
| WO-2015179955-A1 | UBA5 INHIBITORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015179955-A1 | UBA5 INHIBITORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2015-12-03 | — | — | WO | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1268626-B1 | POROUS POLYMER VESICLE AND A PROCESS FOR THE PREPARATION THEREOF | MIP TECHNOLOGIES AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1776949-A2 | A porous, molecularly imprinted polymer and a process for the preparation thereof | MIP Technologies AB (SE) | 2007-04-25 | — | — | EP | disclosed |
| US-20050189291-A1 | Porous, molecularly imprinted polymer and a process for the preparation thereof | MIP TECHNOLOGIES AB (SE) | 2005-09-01 | — | — | US | disclosed |
| US-6881804-B1 | Porous, molecularly imprinted polymer and a process for the preparation thereof | MIP TECHNOLOGIES AB (SE) | 2005-04-19 | — | — | US | disclosed |
| EP-1501850-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093290-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1268626-A1 | A POROUS, MOLECULARLY IMPRINTED POLYMER AND A PROCESS FOR THE PREPARATION THEREOF | MIP Technologies AB (SE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001032760-A1 | A POROUS, MOLECULARLY IMPRINTED POLYMER AND A PROCESS FOR THE PREPARATION THEREOF | MIP TECHNOLOGIES AB (SE) | 2001-05-10 | — | — | WO | disclosed |
| US-4230708-A | SYNERGISTIC | STICHTING REGA V.Z.W. (BE) | 1980-10-28 | — | — | US | disclosed |
| US-3983097-A | Method of producing high molecular derivatives | OKUBO TSUNEO | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077284-B2 | UBA5 inhibitors | UBQLN2, UBTF, UBQLN1 | ADORA2A 4363/4885ADORA1 4523/4885ADORA2B 4493/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | ADORA2A 4792/4885ADORA1 4696/4885ADORA2B 4849/4885 |
| US-20170107247-A1 | UBA5 INHIBITORS | UBQLN2, UBTF, UBQLN1 | ADORA2A 4363/4885ADORA1 4523/4885ADORA2B 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.